Docetaxel and Intermittent Erlotinib in Patients with Metastatic Non-small Cell Lung Cancer; A Phase II Study From The Hellenic Cooperative Oncology Group
AuthorKaravasilis, V.; Kosmidis, P.; Syrigos, K. N.; Mavropoulou, P.; Dimopoulos, M. A.; Kotoula, V.; Pectasides, D.; Boukovinas, I.; Klouvas, G.; Kalogera-Fountzila, A.; Papandreou, C. N.; Fountzilas, G.; Briasoulis, E.
Aim: To determine the more effective dosing sequence of intermittent erlotinib and docetaxel for treating chemotherapy-naive patients with advanced Non-Small Cell Lung Cancer (NSCLC). Patients and Methods: Patients were randomized to receive daily erlotinib for 12 consecutive days prior to docetaxel (Arm A) or after docetaxel (Arm B). Progression-free survival (PP'S) was the primary end-point; secondary end-points were overall survival (OS) and objective response rate (ORR). Results: Fifty eligible patients received a total of 226 treatment cycles (median: 3). Median PFS and OS were 3.6 months and 10.5 months, respectively (differences were not statistically significant between the two arms). Neutropenia grade 3 and 4 occurred in 15 patients, while two patients developed grade 3 diarrhea. There were two treatment-related deaths (pulmonary embolism and non-neutropenic sepsis). Conclusion: intermittent administration of erlotinib does not appear to improve the clinical outcome of single-agent docetaxel chemotherapy in unselected patients with NSCLC in the first-line setting.